Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Juno Therapeutics, A Subsidiary Of Celgene

Clinical trials sponsored by Juno Therapeutics, A Subsidiary Of Celgene, explained in plain language.

Now part of Bristol-Myers Squibb Company BMY NYSE

A biotech developing CAR-T cell therapies, now part of Bristol-Myers Squibb.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Second chance: nonconforming CAR-T therapy offered to lymphoma patients

Disease control AVAILABLE

This program provides access to a CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) that didn't meet all commercial quality standards. It is for adults with large B-cell lymphoma who were already prescribed liso-cel as part of their care. Patients receive chemotherapy…

Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control

Last updated Jun 27, 2026 08:03 UTC